DMRA · Healthcare
Damora Therapeutics Inc
14/100
Smart-money confidence1 of 3 sources positive
Bearish — money moving out
No standout activity across the feeds we track.
Hedge funds
18
Congress
No data
Insiders
No data
Cross-source blend of hedge-fund breadth, Congress trades, and insider Form 4s. ·
how the score works
Market cap
$1.9B
Industry
Biotechnology
Sector
Healthcare
Exchange
NasdaqCM
About DAMORA THERAPEUTICS INC
Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company's lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients. It also develops GB3226, a small molecule inhibitor of ENL-YEATS and FLT3 for the treatment of acute myeloid leukemia. Damora Therapeutics,…
Who's behind the signal
Every informed buyer we can see on DMRA, across all three feeds.
Hedge funds · 3
Viking Global Investors
New position
Millennium Management (Englander)
New position
Point72 (Steve Cohen)
Increased +995%
Congress · 0
No congressional trades on record.
Insiders
No significant Form 4 insider activity in the window.
Not a model pick — but on our radar.
DAMORA THERAPEUTICS INC isn't in the top-10 model right now, but 3 tracked investors hold it. Everything below is real signal from public filings — treat this as a watch candidate, not a conviction call.
3
Investors
2
New positions
1
Increasing
0
Decreasing
0
Unchanged
Price History
Loading price data...
Return:
High:
Low:
Who's Holding This Stock
Position sizes and recent activity from tracked institutional investors
Trust weight: 1.5×
% of portfolio
0.2%
Position change
NEW
0.2% of Viking Global Investors's portfolio
Trust weight: 1.0×
% of portfolio
0.0%
Position change
NEW
0.0% of Millennium Management's portfolio
Trust weight: 1.1×
% of portfolio
0.1%
Position change
+995%
0.1% of Point72's portfolio
Portfolio Allocation
How much of each investor's portfolio is allocated to DAMORA THERAPEUTICS INC
⚠ Disclaimer: This page is for informational purposes only. Holdings data from SEC EDGAR 13F filings, delayed up to 135 days. Not a recommendation to buy or sell DAMORA THERAPEUTICS INC or any security.
Get the Weekly Update
Every week, we'll send you what Buffett, Dalio, Ackman and 47 other legendary investors are buying — free, straight from their SEC filings.
Free forever · No spam · Unsubscribe anytime